Doxycycline in the prevention of hepatic dysfunction: an evaluation of its use following jejunoileal bypass in humans
R. L. Yost, M. C. Duerson, W. L. Russell and J. P. O'Leary
A prospective randomized study was carried out to evaluate doxycycline
hyclate in the prevention of hepatic dysfunction following jejunoileal
bypass for morbid obesity. Forty-five patients were entered into the study
and were observed for a year or more. Patients received either 100 mg of
doxycycline hyclate twice daily on postoperative days 5 through 10 and then
100 mg daily for six weeks, or no drug. At six weeks, 12 weeks, and 12
months after the operation, biochemical levels were measured. After one
year all patients had a liver biopsy. Doxycycline, in the regimen, was not
demonstrated to be of value in the prevention of hepatic dysfunction in
these patients. A lack of correlation was demonstrated between the
biochemical definition of hepatic dysfunction and liver histopathology.
